The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result59% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_2	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result56% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_3	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result49% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_4	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_5	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result78% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_6	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result78% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_7	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_8	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result60% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_9	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result38% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_10	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_11	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_12	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result38% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_13	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_14	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result95% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_15	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_16	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result77% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_17	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_18	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_19	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_20	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_21	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result38% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_22	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_23	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result95% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_24	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_25	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result77% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_26	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_27	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_28	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result80% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_29	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result78% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_30	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result40% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_31	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_32	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result82% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_33	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result84% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_34	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result89% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_35	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_36	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineAsPC-1	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_37	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+6 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicitySlight hepatotoxicity	In-vivo resultReduction in tumor volume to 230 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_38	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 198 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_39	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_40	Virus nameAdenovirus	Virus strainAdCMV/GFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutant with E1 deletion carrying a green fluorescent protein (GFP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityHighly toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result13% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_41	Virus nameAdenovirus	Virus strainAd dl1520	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b mutant with 827-bp deletion and a point mutation with premature stop codon in the E1B55K coding region	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result54% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_42	Virus nameAdenovirus	Virus strainAd-cycE	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivates CDK2 and targets the transcriptional repressor pRb	Clinical trialNA	PMID26475304
IDOV_43	Virus nameAdenovirus	Virus strainAdCMV/GFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutant with E1 deletion carrying a green fluorescent protein (GFP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine lung cancer cell line	Cell lineED-1	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityHighly toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result22% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_44	Virus nameAdenovirus	Virus strainAd dl1520	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b mutant with 827-bp deletion and a point mutation with premature stop codon in the E1B55K coding region	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine lung cancer cell line	Cell lineED-1	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result55% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_45	Virus nameAdenovirus	Virus strainAd-cycE	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine lung cancer cell line	Cell lineED-1	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result55% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivates CDK2 and targets the transcriptional repressor pRb	Clinical trialNA	PMID26475304
IDOV_46	Virus nameAdenovirus	Virus strainAd-cycE	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale FVB/NCr mice isograft for 5.0E+6 cells ED-1 murine lung cancer cell lines	In-vivo virus concentration1.5E+9 IFU (on 0, 2, 4 and 6 days)	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 52 cubic millimeter compared to control 150 cubic millimeter after 36 days	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectActivates CDK2 and targets the transcriptional repressor pRb	Clinical trialNA	PMID26475304
IDOV_47	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result57% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_48	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with etoposide (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.67 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result24% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_49	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with epirubicin (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.46 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result16% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_50	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with doxorubicin (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.88 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result26% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_51	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with vincristine (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.79 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result25% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_52	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with colchcine (0.02 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.81 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result28% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_53	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_54	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with etoposide (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.27 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result4% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_55	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with epirubicin (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.31 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result4% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_56	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with doxorubicin (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.33 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result6% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_57	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with vincristine (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.89 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result12% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_58	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with colchcine (0.02 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.78 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_59	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_60	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_61	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result40% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_62	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result2% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_63	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_64	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_65	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result60% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_66	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result4% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_67	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result1% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_68	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_69	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_70	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result96% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_71	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result80% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_72	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result20% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_73	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_74	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_75	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_76	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_77	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_78	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_79	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_80	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_81	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_82	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result85% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_83	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result35% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_84	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (YB-1 gene knockdown)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result1% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_85	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_86	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_87	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result20% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_88	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result2% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_89	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result1% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_90	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_91	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_92	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_93	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result75% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_94	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast cancer line	Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result16% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_95	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration0.01 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_96	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration0.1 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_97	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration1 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_98	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration10 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_99	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration0.01 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_100	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismClinical lung adenocarcinoma tissue (Primary cancer cells, Stage IA)	In-vivo virus concentration0.1 MOI	In-vivo toxicityNA	In-vivo result100% cancer cell viability	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462